I am currently the Global Program Head for the CART19 program, which is a collaboration between the University of Pennsylvania & Novartis. I am a clinical hematologist-oncologist by training (Cornell), with a BA in German Literature (Princeton) and an MD (Yale). I spent 7 years in clinical drug development at Roche & Sandoz/Novartis, 1.5 yrs as an equity analyst at a biotech hedge fund (Ursus Capital), then 11 yrs in Business Development & Licensing in Novartis Oncology. I was head of the group for 4 years before assuming my current position.
Retired from engineering/management since 1997. Largely biotech, but some other stocks and real estate investor for over 25 years. Enjoy skiing, sailing, sports. I enjoy the role of Devil's Advocate, so some of what I say may be to provoke discussion, and may not reflect my actual opinion.
I'm currently undergoing treatment for Acute Lymphoblastic Leukemia. I had planed to be skiing now, but sometimes life gets in the way of your plans. While I'm confident of achieving remission, I intend to be very critical of the FDA for the way drug testing is done. I'm strongly in favor of streamlining the clinical trial process, especially when related to drugs for potentially terminal diseases. I am scheduled for stem cell transplantation late this month (4/15).
Larry White is a featured analyst at ElliottWaveTrader focusing on mining stocks. Larry joined as a member of EWT in October 2012 and quickly shifted his focus to mining stocks as well as the GDX and GDXJ mining ETFs. Prior to trading, held management and executive roles for organizations such as Toshiba, ISOETEC, and Panasonic.
I am a private investor with a broad portfolio diversified across sector and size. Most of my writing, and much of the speculative portion of my portfolio, focuses on small and mid-cap companies in the healthcare and biotechnology sector. This sector provides the opportunity for outsize rewards, though one must be willing to accept significant risk. My background has exposure to healthcare investing and involvement with operating companies, which I believe provides me with a unique perspective. Currently I am an Associate for Finance and Business development at a clinical stage oncology company called Oncoceutics. Previously I was an Analyst at Osage University Partners, a venture capital firm focused on investing in companies developing technologies licensed from universities across a broad spectrum of opportunities including life sciences, information technology, cleantech, hardware and advanced materials. Prior to that, I worked for a grant program directed at life science technology commercialization at the University City Science Center. I also have worked at BlackRock Asset Management in an operations role with the money market and municipal bond fund groups.
I have a B.S. in Finance and Entrepreneurship with a minor in Biological Sciences from Drexel University, and hold the Chartered Financial Analyst (CFA) designation.